Seattle’s A-Alpha Bio Raises $2.8M Seed Round to Advance AlphaSeq Drug Discovery Platform

Seattle startup A-Alpha Bio raised $2.8 million in seed funding to advance its genetically engineered protein analysis platform, AlphaSeq, which accelerates drug candidate evaluation by sorting millions of protein interactions. The round was led by OS Fund and included investors such as Madrona Venture Group and AME Cloud Ventures.

RRandolph Lopez DDavid Younger AA-Alpha Bio